The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.

Most patients with MASH stay on resmetirom at 1 year, but Medicaid coverage was tied to lower odds of filling a first prescription within 30 days.

A 20-year review traces how immune checkpoint inhibitors became a cornerstone of lung cancer treatment.

David T. Plante, MD, PhD, explains that separating mood-related sleepiness from primary hypersomnia relies on the course of illness and sleep testing.

Phase 3 Viti-Up trials show Rinvoq (upadacitinib) JAK inhibitor boosts facial and body repigmentation in nonsegmental vitiligo, with familiar safety.

A population-based study of 1102 Canadian children found infants with bone and soft tissue tumors had poorer survival, driven largely by treatment deaths.

Liver disease disparities tied to insurance and race spanned HCC surveillance, transplant listing, and drug access in data at The Liver Meeting 2026.

A case report describes the first KRAS::ETNK1 fusion in MDS/MPN with eosinophilia; the fusion disappeared when the disease relapsed as AML.